Radiopharmaceuticals and Methods of Radiolabeling

  • Gopal B. Saha


A radiopharmaceutical is a radioactive compound used for the diagnosis and therapeutic treatment of human diseases. In nuclear medicine nearly 95% of the radiopharmaceuticals are used for diagnostic purposes, while the rest are used for therapeutic treatment. Radiopharmaceuticals usually have no pharmacologic effect, because in most cases they are used in tracer quantities. In these cases, they do not show any dose—response relationship and thus differ from conventional drugs. Because they are administered to humans, they should be sterile and pyrogen free, and they should undergo all quality control measures required of a conventional drug. A radiopharmaceutical may be a radioactive element such as 133Xe, or a labeled compound such as 131I-iodinated proteins and 99mTc-labeled compounds.


Label Compound Stannous Chloride Label Yield Strong Ligand Ethyl Cysteine Dimer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  1. Billinghurst MW, Rempel S, Westendorf BA. Radiation decomposition of techne-tium-99m radiopharmaceuticals. J Nucl Med. 1979; 20:138.PubMedGoogle Scholar
  2. Clark MJ, Podbielski L. Medical diagnostic imaging with complexes of Tc-99m. Coord Chem Rev. 1987; 78:253.CrossRefGoogle Scholar
  3. Deutsch E, Nicolini M, Wagner HN, Jr eds. Technetium in Chemistry and Nuclear Medicine. Verona: Cortina International; 1983.Google Scholar
  4. Dewanjee MK. The chemistry of 99mTc-labeled radiopharmaceuticals. Semin Nucl Med. 1990; 20:5.PubMedCrossRefGoogle Scholar
  5. Dewanjee MK. Radioiodination: Theory, Practice and Biomedical Application. Boston: Kluwer Academic; 1992CrossRefGoogle Scholar
  6. Eckelman WC, Coursey BM, eds. Technetium-99m. Int J Appl Radiat hot. 1982; 33:843.Google Scholar
  7. Eckelman WC, Steigman J, Paik CH. Radiopharmaceutical chemistry. In: Harpert J, Eckelman WC, Neumann RD, eds. Nuclear Medicine: Diagnosis and Therapy. New York: Thieme Medical; 1996:213.Google Scholar
  8. Jones AG, Davison A. The chemistry of Tc(I), II, III, IV. Int J Appl Radiat Isot. 1982a; 33:867.CrossRefGoogle Scholar
  9. Jones AG, Davison A. The relevance of basic technetium chemistry to nuclear medicine. J Nucl Med. 1982b; 23:1041.PubMedGoogle Scholar
  10. Kotegov KV, Pavlov ON, Shvedov VP. Technetium. In: Advances in Inorganic Chemistry and Radiochemistry. New York: Academic Press; 1968:2.Google Scholar
  11. Lathrop KA, Harper PV, Rich BH, et al. Rapid incorporation of short-lived cyclotron produced radionuclides into radiopharmaceuticals. In Radiopharmaceuticals and Labeled Compounds. Vienna: IAEA; 1973: 471.Google Scholar
  12. Nicolini M, Bandoli G, Mazzi U, eds. Technetium in Chemistry and Nuclear Medicine. Verona: Cortina International; 1986.Google Scholar
  13. Richards P, Steigman J. Chemistry of technetium as applied to radiopharmaceuticals. In: Subramanian G, Rhodes BA, Cooper JF, Sodd VJ, eds. Radiopharmaceuticals. New York: Society of Nuclear Medicine; 1975:23.Google Scholar
  14. Srivastava SC, Meinken G, Smith TD, Richards P. Problems associated with stannous 99mTc-radiopharmaceutical. In: Welch MJ, ed. Radiopharmaceuticals and Other Compounds Labelled with Short-Lived Radionuclides. New York: Pergamon Press; 1977:83.Google Scholar
  15. Steigman J, Eckelman WC. The Chemistry of Technetium in Medicine. Nuclear Medicine Series. NAS-NS-3204. Washington: National Head Press; 1992.Google Scholar
  16. Wilbur DS, Hadley SW, Hylarides MD, et al. Development of a stable radio-iodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J Nucl Med. 1989; 30:216.PubMedGoogle Scholar
  17. Yalow RS, Berson SA. Labeling of proteins—Problems and practices. NY Acad Sci. 1966; 28:1033.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Gopal B. Saha
    • 1
  1. 1.Department of Nuclear MedicineThe Cleveland Clinic FoundationClevelandUSA

Personalised recommendations